Teacher Retirement System of Texas Has $4.55 Million Position in IQVIA Holdings Inc. $IQV

Teacher Retirement System of Texas lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 10.5% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 23,967 shares of the medical research company’s stock after selling 2,807 shares during the quarter. Teacher Retirement System of Texas’ holdings in IQVIA were worth $4,552,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of IQV. Verdence Capital Advisors LLC bought a new position in IQVIA during the 2nd quarter worth $3,612,000. Amundi grew its stake in shares of IQVIA by 46.3% in the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after acquiring an additional 405,250 shares in the last quarter. Diversified Trust Co increased its position in IQVIA by 57.2% during the third quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock worth $8,087,000 after acquiring an additional 15,487 shares during the period. Act Two Investors LLC acquired a new stake in IQVIA in the 2nd quarter worth about $26,528,000. Finally, Oregon Public Employees Retirement Fund boosted its holdings in IQVIA by 37.1% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 19,463 shares of the medical research company’s stock valued at $3,697,000 after purchasing an additional 5,271 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on IQV. UBS Group lifted their price target on shares of IQVIA from $250.00 to $280.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. TD Cowen upped their target price on IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a research report on Thursday, January 22nd. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Evercore ISI boosted their price target on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research note on Wednesday, October 8th. Finally, BMO Capital Markets started coverage on shares of IQVIA in a research note on Thursday, November 13th. They set an “outperform” rating and a $260.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $251.06.

IQVIA Stock Performance

NYSE:IQV opened at $241.03 on Wednesday. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The stock’s 50-day simple moving average is $230.03 and its 200 day simple moving average is $207.28. The firm has a market capitalization of $41.05 billion, a PE ratio of 33.06, a price-to-earnings-growth ratio of 2.44 and a beta of 1.36.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter in the previous year, the firm earned $2.84 earnings per share. The business’s quarterly revenue was up 5.2% on a year-over-year basis. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.